Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Xylem, Inc. — how do they compare? Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B), while Xylem, Inc. trades at $102.3 (market cap $23.77B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5.4× Xylem, Inc.'s market cap, and Xylem, Inc. pays a 1.69% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Xylem, Inc. for 50 Days on average.
| VRTX | XYL | |
|---|---|---|
Market Cap | $128.16B | $23.77B |
Volume | 806,603 | 2,477,250 |
Sector | Health | Industrials |
52-Week High | $557.96 | $152.95 |
52-Week Low | $407.37 | $100.92 |
Typical Hold Time | 120 Days | 50 Days |
Enterprise Value | $122.29B | $25.55B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Xylem (XYL) trades at $101.99, down 2.48% today, amid bearish technical signals but strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected October 27. Revenue grew from $5.5B in 2022 to $9.04B in 2025, while net income margin expanded to 10.59%. Recent acquisitions of Cornell Pump and Roper Pump strengthen industrial presence.
Outlook remains positive with 47.5% analyst buy ratings and $149.13 consensus price target, representing 46% upside. Key risks include China weakness and higher debt from recent note offerings. The stock offers value with P/E of 24.24 and consistent dividend payments, though technical indicators suggest near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
